Therapeutic potential of oxadiazole or furadiazole containing compounds

BMC Chemistry

Table 6 In vitro cytotoxicity (IC₅₀Μ)^a data of compounds (9a-j) [30]

Compound	A549^bc	MCF-7^d	A375^e	HT-29^f
9a	1.20 ± 0.16	0.098 ± 0.004	2.56 ± 0.36	0.012 ± 0.001
9b	0.023 ± 0.006	0.011 ± 0.001	–	1.90 ± 0.71
9c	2.30 ± 0.21	2.19 ± 0.28	–	8.30 ± 1.60
9d	3.56 ± 0.19	2.11 ± 0.23	6.13 ± 1.12	7.14 ± 0.86
9e	5.02 ± 1.02	12.4 ± 0.96	–	–
9f	0.27 ± 0.02	1.07 ± 0.59	2.81 ± 0.25	1.55 ± 0.65
9 g	0.013 ± 0.001	0.80 ± 0.15	1.05 ± 0.53	1.24 ± 0.17
9 h	1.02 ± 0.50	0.010 ± 0.004	1.99 ± 0.29	3.78 ± 0.16
9i	13.9 ± 0.54	18.50 ± 0.86	8.23 ± 1.35	–
9j	0.90 ± 0.09	0.12 ± 0.01	0.39 ± 0.012	1.10 ± 0.54
Combretastatin-A4	0.11 ± 0.01	0.18 ± 0.01	0.21 ± 0.02	0.93 ± 0.03

^aEach data represented as mean ± S.D values. From three different experiments performed in triplicates, ^bcA549: Human lung cancer cell line, ^dMCF-7: Human breast cancer cell line, ^eA375: Human melanoma cancer cell line, ^fHT-29: Human colon cancer cell line. –: Not active

ISSN: 2661-801X